Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price2.52 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-01Read Markup2.40+5.0% to today ✓Distribution gives way to Markup after a 23% slide in 3 weeks
2026-10-11Read Distribution3.13-19.5% to today ✓Markdown gives way to Distribution after a 6% slide in 9 days
2026-10-02Read Markdown3.32-24.1% to today ✓Markup gives way to Markdown after a 374% rise in 5 weeks
2026-08-26Read Markup0.70+260.0% to today ✓Accumulation gives way to Markup after a 10% rise in 8 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Cycurion Inc holds its Markdown at $2.52. Consolidating, no directional conviction, held for 25 days.
As held on the ledger · 2026-11-04
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 25 days
Price at the screen
$2.52
Valuation
0.09 trailing · -1.17 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.95
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
24.61%
Below 33%
Interest-bearing debt is just 24.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
25.01%
Below 49%
Money owed to the company is 25.0% of assets, under the 49% limit.
Pass
Revenue purity
0.18%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Cycurion clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 25%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CYCU's ethical verdict changes
Today CYCU passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CYCU trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup · changed$2.40+11.1%Entry 9
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $7.
2026-10-25Distribution$2.16-31.0%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 31.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $7.
2026-10-11Distribution · changed$3.13-5.7%Entry 7
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $7.
2026-10-02Markdown · changed$3.32+374.3%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 374.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $7.
2026-08-26Markup · changed$0.70+121.5%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 121.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $7.
2026-07-26Accumulation$0.32-50.4%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 50.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $7.
2026-07-18Accumulation$0.64+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $7.
2026-07-03Accumulation$0.64+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Accumulation$0.64Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.